Skip to main content
. 2024 Apr 18;12(4):895. doi: 10.3390/biomedicines12040895
HR Hormone receptor
ER Estrogen receptor
PR Progesterone receptor
HER2 Human epidermal growth factor 2
TNBC Triple-negative breast cancer
CAR-T Chimeric antigen T Cell
CTLA-4 Cytotoxic T-lymphocyte antigen
PD-1 Programmed cell death protein 1
PD-L1 Programmed death-ligand 1
OS Overall survival
DFS Disease-free survival
ORR Overall response rate
DCR Disease control rate
PFS Progression-free survival
ISAC Immune-stimulating antibody conjugate
MTD Maximum tolerable dose